Compare CPSH & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | INKT |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4M | 51.7M |
| IPO Year | 1987 | 2021 |
| Metric | CPSH | INKT |
|---|---|---|
| Price | $3.20 | $11.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 84.6K | 20.6K |
| Earning Date | 10-29-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,321,555.00 | N/A |
| Revenue This Year | $55.87 | N/A |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 38.22 | N/A |
| 52 Week Low | $1.40 | $4.56 |
| 52 Week High | $4.89 | $76.00 |
| Indicator | CPSH | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 50.06 |
| Support Level | $3.12 | $11.33 |
| Resistance Level | $3.25 | $12.31 |
| Average True Range (ATR) | 0.17 | 0.73 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 25.27 | 46.54 |
CPS Technologies Corp provides material solutions to the transportation, automotive, energy, computing/Internet, telecommunications, aerospace, defense, and oil and gas end markets. Its primary material solution is metal matrix composites (MMCs), which are a class of materials consisting of a combination of metal and ceramic. The company designs, manufactures and sells custom MMC components, which manages the performance and reliability of systems in the end markets. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.